Thank you. Henrik. Let's now turn to the business update. Third quarter net sales of 28.5 million were in line with our expectations. As we also saw in previous years, the third quarter is affected by the European summer vacation period. We saw demand naturally soften during August and September. Despite this seasonal effect, we delivered 41% growth compared to Q3 last year. We have now treated more than 1,200 patients with Pepaxti across Europe since our EMA approval in 2022. These heat maps are comparing Q3 from 2023 up to 2026. Our geographic footprint and prescriber base have expanded substantially across Germany, Italy and Spain. This growing real-world clinical experience triggers independent RWE publications, which in turn fuels the peer-to-peer recommendations that are so critical to physicians managing patients. That requires individualized treatment. Following an approved label expansion into an earlier line, we would have the potential to double both our addressable patient population and the average treatment cycle length in the third line. Looking at our clinical position under our current fourth-line label, real-world data and clinical experience consistently point to three distinct patient profiles where Pepaxti makes a clear difference. First, an option for patients unable to receive immunotherapy due to comorbidities, frailty, infections, and quality of life limitations. Second, as an ideal bridge between immune-based therapies, offering non-cross-resistant disease control while allowing for T cell or antigen reset. Or antigen reset, and third, as a proven salvage option for patients who have relapsed or become refractory after BCMA or CAR-T therapies. Following a potential EMA approval, this positioning would become even stronger as part of our pre-launch activities for the third-line label expansion. We have gathered extensive insights from key opinion leaders across Europe. The feedback is remarkably consistent and confirms an unmet need in the third line for non-immunotherapy mechanisms that complement the first and second line regimens. Moving into the third-line would mean Pepaxti is a strategic option for both patients who cannot receive immunotherapy, and as an ideal bridge between immunotherapies earlier in the treatment journey. Just yesterday, we announced that two independent, multicenter, real-world studies from Spain and Italy have been accepted for presentation at ASH in December. The studies, covering in total 82 heavily pretreated patients, further validate Pepaxti's clinical utility and manageable safety profile. Both post-immunotherapy and as a bridge to subsequent immunotherapies. Let's look closer at our key markets, starting with Germany. Germany is the European market with the largest potential for us, and it is also the market where the summer vacation period had the most pronounced seasonal impact. According to September competitor sales data, the overall market in Germany was flat, meaning this is not only the case for us, but for competitors as well. Through commercial discipline and the sharpened business model we implemented earlier this year. We continue to steer our German operations steadily towards country-level profitability. In parallel, our prospective real-world evidence study, MARINA, is progressing and helping us generate experience with office-based hematologists post the hopefully positive EMA decision; the MARINA study team at IO Medical will submit an amendment for the inclusion criteria to reflect the new label, with inclusion of patients from the third line. As you can see on the map and the graph on the right, our German prescriber base continues to grow quarter over quarter. Once physicians gain clinical experience with Pepaxti, they appreciate its profile and continue to prescribe it. Our German team is fully focused on unlocking both new prescribers and earlier line usage, as we are still in later lines in Germany. Moving to Italy. Even if August and September did slow down due to the vacation period, Italy remains a key growth contributor. Italy is our most mature market in terms of clinical experience and fourth-line usage, demonstrating the highest estimated number of treatment cycles per patient based on our sales data, but also confirmed by the real-world data that will be presented at ASH. This success is driven by established market access all the way down to the hospital level, and a very positive clinical experience that drives accurate patient identification and demand. This positive real-world experience is further reinforced by the Italian multicenter study of 42 heavily pretreated patients accepted for ASH. This study demonstrates a strong 38% overall response rate and a 13.5-month median overall survival across a median of five treatment cycles, providing reliable disease control and manageable tolerability. Pepaxti enabled 67% of these patients to proceed to a subsequent treatment, including novel immunotherapies such as bispecific antibodies and CAR-T therapies. In Spain, even though the third quarter was affected by the summer vacation period, sales continued at a higher level than in the previous quarter. Our team has worked with great resilience alongside key opinion leaders to keep expanding our footprint across the countries, as illustrated by the heat map. A great example of the scientific engagements in Spain is the Spanish registry study of 40 heavily pretreated patients accepted for ASH. The study demonstrates a 32.5% overall response rate, an 8.3 month duration of response, and an encouraging 15.7 month median overall survival. Even among the subgroup of last-resort patients previously exposed to anti-BCMA and/or anti-GPRC5D immunotherapies. Treatment achieved a 26% response rate and a 23.2-month median overall survival. Looking at our broader European commercialization roadmap, our phased rollout has been built around an estimated 1.5 billion SEK annual market potential and our fourth-line label protected by market exclusivity until 2037. Phase one markets, Germany, Spain, Italy, Austria, and Greece, represent roughly 50% of that potential, where we are already established. We are actively evaluating strategic options, including new partnership discussions, to ensure we capture the full potential of Europe over time.
Let's look at what a European Commission approval of our type two variation could mean in practice. Currently, Pepaxti is indicated for fourth-line-plus patients who have received at least three prior lines of therapy and are triple-class refractory; however, following a positive EC approval, Our label would expand to adult patients who have received at least two prior lines of therapy, meaning third-line and later, and whose disease is refractory to lenalidomide and their last line of therapy. Removing the triple-class refractory requirement is a major shift that could facilitate earlier and much more frequent patient identification for clinicians. This potential label expansion acts as a powerful commercial and financial multiplier across three dimensions. First, on the commercial side, removing the triple-class refractory barrier and moving to earlier lines would effectively double our addressable European patient population. And as shown in the Phase 3 OCEAN trial, earlier intervention allows patients to remain on therapy longer, doubling the average number of treatment cycles per patient in third line, which would unlock potential far beyond our 1.5 billion SEK estimate currently. Second, regarding market access and pricing, the German basket pricing approach, which averages modern third-line therapies, establishes an attractive comparative price anchor. The German rules would allow immediate launch, giving third-line patients access to Pepaxti while we are negotiating the price. This is very positive for both patients and our commercialization. Third, on medical need and scalability. Pepaxti fills a growing gap for a non-immunotherapy mode of action following first and second-line relapse, which can support our direct presence in Germany, Austria, Italy, and Spain and the value of our partnerships such as SALUS in CEE.
Looking at the timeline, we have thus far executed on this regulatory process rapidly. Following our submission to EMA this summer, we received a positive CHMP opinion in September and expect the formal European Commission decision in the coming weeks, as it should follow no later than 60 days following a CHMP decision. Our immediate priority following a positive decision is to submit a German reimbursement dossier within approximately one month of the EC decision, enabling an immediate commercial launch in the third-line in Germany. In parallel, we are preparing our third-line launches in Italy and Spain and stand ready to submit our market access dossiers as soon as local procedures allow. To illustrate this at the patient level, multiple myeloma is a marathon. It is not a sprint. With each relapse, the tumor burden accelerates, and patients become increasingly frail, both from their disease and from the side effects of prior treatments. By expanding our indication to support third-line and less refractory fourth-line patients, we would be able to bring the benefits of Pepaxti to patients earlier in their disease course, when they are fitter and can stay longer on treatment. Looking at the overall treatment landscape of myeloma, it has evolved with multiple launches in the first, second, and fourth lines over the last few years. Patients now have several options with immunomodulators, anti-CD38 antibodies, proteasome inhibitors, bispecifics, CAR-Ts, and ADCs. What is important to notice is that many of these drugs are targeting BCMA and utilizing the immune system, and as many of these options are already used in earlier lines, physicians increasingly need a differentiated non-cross-resistant mode of action, like our PDC in the third line and beyond. Turning to our partnership and geographic expansion in Central and Eastern Europe. Our partner SALUS made rapid progress by securing a list price in Slovenia in line with the German list price in August. While Slovenia is a smaller market in terms of volume, it serves as a critical reference pricing anchor across the entire CEE region, providing a solid foundation as SALUS now begins to submit reimbursement dossiers in other countries.
In Japan, our partnership dialogues have continued through active engagements, both remotely and in person, with multiple potential partners during the third quarter. In addition, we have met with the top KOLs in Japan and confirmed that they do see the need for Pepaxti as an option that complements immunotherapies. Japan is slightly behind in experience with immunotherapy, but the trend is clear. There are patients progressing on immunotherapy. And there are patients that cannot get immunotherapy due to comorbidities and frailty. This is also observed in Japan. Let's now move to our pipeline, where we have just recently achieved a clinical breakthrough. We have advanced our pipeline into the clinic with a focus on CNS tumors, starting with glioblastoma. The single greatest hurdle in neuro-oncology is the lack of blood-brain-barrier penetration, which causes more than 90% of systemic cancer drugs to fail because they simply cannot reach the tumor. Rather than jumping straight into a costly phase one trial, we designed the capital-efficient INSULA Window of Opportunity study of approximately ten patients at Oslo University Hospital using our approved PDC drug as a clinical probe to test membrane penetration rapidly, and in October, data from the first three patients was concluded to be positive. Let's look closer at what we announced on October 9th from the INSULA study. First, we confirmed blood-brain-barrier penetration via biopsies from resected tumor tissue. In the first patients. The first three evaluated patients demonstrated clear and consistent presence of the active compound. Meeting our primary objective, we achieved pharmacological concentrations completely in line with our preclinical models. Second, we saw a consistent and favorable safety profile. Treatment has been well-tolerated, with no major drug-related toxicity and no unexpected surgical complications. Remarkably, the first patient transitioned into the study's open-label extension and has received five monthly cycles without any new tumor-related neurological symptoms. Together, this marks a critical clinical proof of concept for our PDC platform in CNS tumors. Transforming our brain cancer program from an ambitious preclinical scientific premise into a clinically validated opportunity in a market projected to grow into the size of approximately 8 billion USD by 2035.
So what will happen next? First, we will complete the pharmacokinetic analysis in cohort one, which includes five patients. Second, we have obtained approval to open cohort two from the Safety Review Committee and will, once fully recruited, conclude the pharmacodynamic data analysis, which is exploratory, but we do hope it will give us some further scientific insights. And third, we will follow the open-label patients and observe how they are doing on a PDC. The INSULA patients have recurrent glioblastoma, meaning the focus is not only on efficacy but safety, and the quality of the time they have left is also of importance. Finally, this human proof-of-concept has triggered us to advance our CMC manufacturing activities, complete clinical study preparations, and execute the next clinical development phase for our PDC pipeline in neuro-oncology. This will, of course, happen in dialogue with regulatory authorities to ensure we generate the evidence needed, while we also reach patients without any treatment options as soon as possible. With a positive CHMP opinion and the European Commission decision around the corner for Pepaxti, a human proof-of-concept in glioblastoma and dedicated financing in place. We look forward to keeping you updated on an exciting fourth quarter, and with that, I would like to thank you for listening, and we will now open up the line for questions.